0000000000157004

AUTHOR

Maija Itälä-remes

showing 3 related works from this author

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

2021

Abstract Background Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). Methods This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. Results We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range,…

PNEUMONIAMalevirusesmedicine.medical_treatmentseasonal human coronavirusHematopoietic stem cell transplantationmedicine.disease_causeDISEASElaw.inventionCoronavirus OC43 HumanCLINICAL CHARACTERISTICSlawCoronavirus 229E HumanRisk FactorsImmunology and AllergyChildRespiratory Tract InfectionsNL63 INFECTIONSCoronavirusOUTCOMESRespiratory tract infectionsSYNCYTIAL VIRUSHazard ratioHematopoietic Stem Cell Transplantationvirus diseasesupper and lower respiratory tract diseaseHCoV-NL63HCoV-229Erespiratory systemMiddle AgedIntensive care unitHospitalizationimmunocompromisedsurgical procedures operativeInfectious Diseasesmedicine.anatomical_structureAcademicSubjects/MED00290Child PreschoolCohortFemaleSeasonsCoronavirus InfectionsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; immunocompromised; immunodeficiency score index; multiplex PCR assay; seasonal human coronavirus; upper and lower respiratory tract diseaseAdultmedicine.medical_specialtyHCoV-OC43AdolescentDIAGNOSISCHINAHCoV-HKU1BetacoronavirusAll institutes and research themes of the Radboud University Medical Centerstomatognathic systemInternal medicinemedicineMajor ArticleRHINOVIRUSHumansallogeneic hematopoietic stem cell transplantationAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryInfantmultiplex PCR assayTransplantationCoronavirus NL63 HumanPARAINFLUENZA VIRUSbusinessimmunodeficiency score indexRespiratory tract
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Canc…

2019

Question What are the outcomes of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy compared with other transplant types in adults with hematologic cancers? Findings In this meta-analysis of 30 studies including 22974 patients, the use of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy appeared to show increased all-cause mortality compared with matched related donors, similar all-cause mortality compared with matched unrelated donors, and reduced all-cause mortality compared with mismatched unrelated donors. Relapse appeared to be increased in lymphoma and similar in acute leukemia compared with matched unrelated don…

OncologyCancer Researchmedicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentOdds ratioHematopoietic stem cell transplantationCochrane LibraryTransplantation03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMeta-analysismedicine030212 general & internal medicineStem cellbusinessCyclophosphamide therapymedicine.drugOriginal Investigation
researchProduct